News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Approves Novartis AG (NVS)'s Simbrinza for Glaucoma


4/22/2013 8:32:39 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Alcon, the global leader in eye care and a division of Novartis, has received US Food and Drug Administration (FDA) approval for Simbrinza suspension, indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. Elevated IOP is the only modifiable risk factor for glaucoma. Glaucoma is a group of eye diseases that lead to progressive damage of the optic nerve and can result in gradual, irreversible loss of vision, and eventually blindness, if left untreated. Simbrinza is a fixed-dose combination medication that offers a wide range of treatment possibilities due to its strong efficacy and ability to decrease elevated IOP by 21- 35 per cent. In addition, it is the only available, fixed-dose combination therapy for glaucoma in the US without a beta blocker.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   
Glaucoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES